Tuesday, Sep 29, 2020 | Last Update : 02:05 PM IST

189th Day Of Lockdown

Maharashtra1351153104994735751 Andhra Pradesh6811616123005745 Tamil Nadu5863975307089383 Karnataka5824584697508641 Uttar Pradesh3908753312705652 Delhi2730982407035272 West Bengal2505802198444837 Odisha212609177585866 Telangana1872111564311107 Kerala179923121264698 Bihar178882164537888 Assam169985139977655 Gujarat1332191132403417 Rajasthan1288591077181441 Haryana1237821059901307 Madhya Pradesh117588932382207 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880
  Business   Companies  06 Aug 2020  Novavax announces COVID-19 vaccine supply deal with Serum Institute

Novavax announces COVID-19 vaccine supply deal with Serum Institute

REUTERS
Published : Aug 6, 2020, 10:16 am IST
Updated : Aug 6, 2020, 10:16 am IST

Novavax reported that its experimental vaccine produced high levels of antibodies against coronavirus in a small, early-stage clinical trial

 Novavax signs Covid-19 vaccine supply deal with India's Serum Institute. (AFP Photo)
  Novavax signs Covid-19 vaccine supply deal with India's Serum Institute. (AFP Photo)

Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.

The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper-middle or high-income countries.

 

The deal was signed on July 30, according to an SEC filing by Novavax.

On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.

Tags: covid-19, coronavirus, vaccine, novavax, serum institute